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Abstract
Islet adaptations to pregnancy were explored in C57BL6/J mice lacking functional receptors for glucagon-like peptide 1
(GLP-1) and gastric inhibitory polypeptide (GIP). Pregnant wild type mice and GIPRKO mice exhibited marked increases in
islet and beta cell area, numbers of medium/large sized islets, with positive effects on Ki67/Tunel ratio favouring beta cell
growth and enhanced pancreatic insulin content. Alpha cell area and glucagon content were unchanged but prohormone
convertases PC2 and PC1/3 together with significant amounts of GLP-1 and GIP were detected in alpha cells. Knockout of
GLP-1R abolished these islet adaptations and paradoxically decreased pancreatic insulin, GLP-1 and GIP. This was associated
with abolition of normal pregnancy-induced increases in plasma GIP, L-cell numbers, and intestinal GIP and GLP-1 stores.
These data indicate that GLP-1 but not GIP is a key mediator of beta cell mass expansion and related adaptations in
pregnancy, triggered in part by generation of intra-islet GLP-1.
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Introduction
GLP-1 and GIP are incretin hormones released from intestinal
enteroendocrine cells in response to feeding [1–3]. In addition to
glucose-dependent stimulation of insulin secretion, they exert a
variety of other actions on beta cells including stimulation of
insulin biosynthesis and beta cell replication together with
protection against chemical attack and inhibition of apoptosis
[1–4]. Other actions of GLP-1 include inhibition of glucagon
secretion, gastric emptying and feeding, with additional positive
effects on cardiac muscle and, in common with GIP, improvement
of cognition and bone formation [5–8]. These attributes of GLP-1
have been captured for treatment of type 2 diabetes by
development of stable GLP-1 mimetics and DPPIV inhibitors
which inhibit the normal rapid degradation of both incretin
hormones [9–11].
Much has been elucidated concerning the pancreatic and
extrapancreatic actions of GLP-1 and GIP together with
mechanisms regulating the secretion of the two incretin hormones
from intestinal L- and K-cells, respectively [4,12–17]. However,
recent studies have opened a whole new aspect of research by
demonstrating that GLP-1 and GIP are not generated exclusively
in the gut but may also be present in islet cells. Thus, recent studies
have shown that the normal proglucagon processing to glucagon
in islet alpha cells by PC2 can be modified by expression of PC1/3
yielding GLP-1 and related peptides normally produced by
intestinal L-cells [18–27]. Accordingly GLP-1 has been demon-
strated by immunochemical staining, immunoassay, bioassay and
mass spectroscopy techniques in both animal and human alpha
cells, giving rise to speculation that islet-derived GLP-1 may play a
key role in beta cell function. Use of antibodies or chemical
antagonists of GLP-1 indicate that GLP-1 released from islet alpha
cells in vitro may stimulate insulin release from adjacent beta cells
via paracrine or local islet cell interactions [24,26]. Further studies
also indicate that GIP (1–42), or more likely the equally
biologically active fragment GIP (1–30) generated by the action
of PC2, is also produced by islet alpha cells [28]. More recently
still, transgenic mice with global deficiency in proglucagon-derived
peptides have been shown to exhibit ectopic expression of
biologically active GIP in islet beta cells [29]. Taken together,
these observations suggest that GLP-1 and GIP are generated
within islets and exert possible unsuspected roles in the functional
regulation of beta cells and other islet cell types.
Some evidence exists for physiological significance of islet-
derived GLP-1 and GIP in terms of insulin secretion [24,26] but
their involvement in the regulation of beta cell mass is possibly
more intriguing given the paucity of agents with such effects and
the loss of beta cells in both type 1 and type 2 diabetes [30–32].
Pregnancy is one of the very few situations associated with
physiological and reversible expansion of beta cell mass not only in
animals, which show remarkable plasticity of insulin secreting cells,
but also in humans [33–38]. Given the positive actions of the two
incretins on beta cell mass, resulting from reciprocal effects on beta
cell proliferation and death [1,2], we examined the role GLP-1
and GIP in islet adaptation to pregnancy using incretin receptor
knockout mice [39–41]. The results reveal an important role of
GLP-1 in pregnancy-induced increases in beta cell mass, mediated
largely by local GLP-1 production in alpha cells. In contrast,
GIPR KO mice demonstrated intact mechanisms of islet
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adaptation to pregnancy, suggesting that islet or K-cell derived




Adult 8-week-old female C57BL/6 mice, GLP-1RKO mice and
GIPRKO mice (n = 6) were bred in house in the Biomedical and
Behavioural Research Unit at University of Ulster, Coleraine. The
original background and generation of these incretin receptor
knockout mice are described elsewhere [39,40]. GLP-1RKO and
GIPRKO mice were backcrossed to wild type C57BL6/J mice for
more than ten generations prior to use in the present study. Mice
were housed individually in an air-conditioned room at 22 6 2uC
with a 12 h light and 12 h dark cycle. Standard rodent pellet diet
(Trouw Nutrition, Northwich, Chesire, UK) and drinking water
were available ad libitum. All animal experiments were carried out
in accordance with the UK Animals (Scientific Procedures) Act
1986 and approved by the University of Ulster Animal Ethics
Review Committee. All necessary steps were taken to ameliorate
any potential animal suffering and animals were sacrificed by
lethal inhalation of CO2 followed by cervical dislocation. For
analysis of pregnancy induced changes, mice were culled at 18.5
day post coitum to procure pancreatic tissues, intestines and
terminal blood samples (non-fasted) and compared to age matched
non-pregnant control mice (n = 6 in each group). Glucose
tolerance, insulin sensitivity, food intake and body weight changes
were not monitored for fear of adverse effects on pregnancy
outcomes.
Immunohistochemistry
Pancreatic tissues and small intestines from non-pregnant and
pregnant mice fixed in 4% paraformaldehyde for 48 h at 4 uC.
The tissues were processed using automated tissue processor (Leica
TP1020, Leica Microsystems, Nussloch, Germany). After embed-
ding, tissues were sectioned at 7 mm using a microtome (Shandon
finesse 325, Thermo scientific, UK). Six pancreatic sections were
picked at an interval of 80 mm for histology. The tissue sections
were deparaffinised and rehydrated through series of ethanol
concentrations. After antigen retrieval at 94 uC for 20 min using
citrate buffer (pH 6.0), the sections were blocked using 10%
normal goat serum and incubated with primary antibody as
appropriate: mouse monoclonal anti-insulin antibody (ab6995,
1:1000; Abcam), gunieapig anti-glucagon antibody (PCA2/4,
1:200; raised in-house), rabbit anti-GLP-1 antibody (XJIC8,
1:200; raised in-house, specific for total GLP-1), rabbit anti-GIP
antibody (RIC34/111J, 1:400; kindly donated by Professor L
Morgan, Guildford, UK), rabbit anti-Ki67 antibody (ab15580,
1:200; Abcam), mouse anti-PC1/3 antibody (ab55543, 1:100;
Abcam) or rabbit anti-PC2 antibody (ab15610, 1:200, Millipore),
overnight at 4 uC. The sections were then incubated with
secondary antibody (Alexa Fluor 488 goat anti-guinea pig IgG –
1:400, Alexa Fluor 594 goat anti-mouse IgG – 1:400, Alexa Fluor
488 goat anti-rabbit IgG – 1:400 or Alexa Fluor 594 goat anti-
rabbit IgG – 1:400) as appropriate for 45 min at 37 uC. The slides
were then mounted using anti-fade mounting medium and viewed
under FITC filter (488 nm) or TRITC filter (594 nm) using
fluorescent microscope (Olympus system microscope, model
BX51) and photographed using the DP70 camera adapter system.
Antibodies selected for immunohistochemical staining of glucagon,
GLP-1 and GIP were highly specific and showed no cross
reactivity with related peptide hormones. For analysis of beta cell
apoptosis, Tunel assay was performed according to manufacturer’s
instructions (In situ cell death kit, Fluorescein, Roche Diagnostics,
UK).
Image analysis
Cell‘F image analysis software (Olympus Soft Imaging Solu-
tions, GmbH) was used to analyse islet parameters including islet
area, beta cell area and alpha cell area, expressed as mm2. The
image folders were coded and the investigator was blinded during
analysis of islet parameters. Number of islets per mm2 of pancreas
and the proportion of islets with central alpha cells were
determined in a blinded fashion. For analysis of islet size
distribution, islets smaller than 10,000 mm2 were designated
‘small’, greater than 10,000 mm2 and less than 25,000 mm2 were
designated ‘medium’ and greater than 25,000 mm2 were designat-
ed ‘large’. Colocalization analysis was carried out using ‘Coloca-
lization finder’ plugin in ImageJ and expressed as Pearson’s
colocalization coefficient. A value close or equal to 21.0
represents no colocalization while a value close or equal to 1.0
represents full colocalization of two antigens. Alpha cells
expressing GLP-1 or GIP with no visible glucagon staining were
designated ‘GLP-1+/GIP+ glucagon2 cells. Ki67 and TUNEL
positive, insulin positive cells were counted in a blinded manner
and expressed as % of total number of beta cells analysed.
Approximately 2000 beta cells per replicate were assessed. The
balance between proliferation and apoptosis was expressed as ratio
of Ki67/Tunel. For analysis of intestinal parameters including L
cell count, K cell count and villus length, serial images of sections
were photographed. Cell‘F image analysis software was used to
determine mucosal area in mm2. Cell count was determined in a
blinded manner and expressed as count per mm2 mucosal area.
Villus length was determined using ‘line’ tool in Cell‘F software
and expressed as mm.
Biochemical analyses
Blood samples were collected in fluoride/heparin microcen-
trifuge tubes (Sarstedt, Numbrecht, Germany) and centrifuged for
30 s at 13,0006 g. Plasma was separated and stored at 280uC
until analysis. Plasma glucose was measured by an automated
glucose oxidase procedure (Beckman Glucose Analyzer). Pancre-
atic and intestinal tissues were extracted using buffer containing
20 mM Tris HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA and 1% Triton6100 and stored at 280 uC. Biochemical
analyses were carried out for insulin by radioimmunoassay [42],
total GLP-1 (GLP-1 total ELISA, EZGLP-1T-36K, Millipore),
GIP (rat/mouse GIP ELISA, EZRMGIP-55K, Millipore) and
glucagon (glucagon chemiluminescent assay, EZGLU-30K, Milli-
pore) by specific enzyme linked immunoassays following the
manufacturers’ instructions. All commercial assay kits have been
shown to exhibit a high degree of specificity.
Statistics
Results were analysed in GraphPad PRISM (Version 5.0) and
presented as mean6 SEM. Statistical analyses were carried out by
unpaired Student’s t test (non-parametric, with two-tailed P values
and 95% confidence interval) and one way ANOVA with
Bonferroni post-hoc test wherever applicable. Results were
considered significant if p,0.05.
Results
Pregnancy significantly increases islet cell mass
Representative islets depicting insulin/glucagon immunoreac-
tivity from non-pregnant and pregnant C57BL/6, GLP-1RKO
and GIPRKO mice are shown in Figure 1A. In C57BL/6 and
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GIPRKO animals, pregnancy significantly increased islet area and
beta cell area by 1.8–2.5 fold and 1.4–2 fold respectively (p,0.05,
Figure 1B, C). However in GLP-1RKO animals, pregnancy did
not increase islet or beta cell area (Figure 1B, C) and quantification
of islet area demonstrated a significant reduction in pregnant
GLP-1RKO mice (p,0.05 vs. C57BL/6 mice, Figure 1B). Alpha
cell area was unaffected by pregnancy in C57BL/6 and GIPRKO
mice but a trend towards reduction in alpha cell area was observed
in GLP-1RKO mice. Alpha cell area was significantly higher in
non-pregnant and pregnant GIPRKO mice compared to C57BL/
6 mice (p,0.01, Figure 1D).
Pregnancy also affected islet size distribution, with percentage of
medium and large sized islets increasing in C57BL/6 mice and
percentage of large islets increasing in GIPRKO mice (Figure 1E).
However in GLP-1RKO animals, pregnancy did not affect islet
size distribution (Figure 1E). Defective GLP-1R signalling
significantly affected islet topology, in that percentage of islets
with centrally located alpha cells was markedly higher than non-
pregnant wild type mice (p,0.001, Figure 1A, F). Representative
images showing islet distribution in pancreas of non-pregnant and
pregnant C57BL/6, GLP-1RKO and GIPRKO mice are shown
in Figure 2A. Pregnancy did not affect number of islets per mm2
pancreas (Figure 2B). Non-pregnant receptor knockout mice
demonstrated significantly lower number of islets compared to
non-pregnant C57BL/6 mice (p,0.05, Figure 2B). Pregnant
GLP-1RKO mice also had a lower number of islets compared to
pregnant C57BL/6 mice (p,0.01, Figure 2B).
Representative islets showing Ki67/insulin, TUNEL/insulin
immuno-reactivity from non-pregnant and pregnant C57BL/6,
GLP-1RKO and GIPRKO mice are shown in Figure 3A.
Pregnancy significantly increased beta cell proliferation and
apoptosis frequency in islet beta cells of all groups (p,0.001,
Figure 3B, C). However, in pregnant GLP-1RKO and GIPRKO
mice, beta cell proliferation frequency was markedly lower when
compared with C57BL/6 mice (p,0.001, Figure 3B). The ratio of
Ki67/TUNEL was higher in pregnant C57BL/6 and GIPRKO
mice when compared with non-pregnant mice, thus favouring
increased beta cell mass (p,0.05, Figure 3D). However in GLP-
RKO mice, ratio of Ki67/TUNEL was not altered by pregnancy.
The ratio of Ki67/TUNEL in pregnant GLP-1RKO and
GIPRKO mice was significantly less than pregnant C57BL/6
mice (p,0.01, p,0.001, Figure 3D).
Pregnancy alters proglucagon processing in alpha cells
Representative islets showing GIP/glucagon, GLP-1/glucagon
colocalization from non-pregnant and pregnant C57BL/6, GLP-
1RKO and GIPRKO mice are shown in Figures 4A and 5A
respectively. Pregnancy did not affect GIP/glucagon colocaliza-
tion in alpha cells in C57BL/6 mice (Figure 4B). GIP expression in
both groups of receptor knockout mice was significantly lowered
by pregnancy (p,0.05, p,0.01, Figure 4B). Interestingly,
pregnancy lowered GLP-1/glucagon colocalization in alpha cells
of C57BL/6 mice (p,0.001, Figure 5B). However this was
primarily due to substantial increase in cells expressing solely GLP-
1, indicated by dotted arrows pointing to GLP-1 immunoreactivity
Figure 1. Islet analysis. A: Representative islets showing insulin (red) and glucagon (green, indicated by arrows) immunoreactivity from non-
pregnant and pregnant C57BL/6, GLP-1RKO and GIPRKO mice are shown. B: Islet area, expressed as mm2. C: Beta cell area, expressed as mm2. D: Alpha
cell area, expressed as mm2. E: Islet size distribution, expressed as % of total islets analysed (n = 15 to 20 islets per animal). F: Islets with central alpha
cells, expressed as percentage of total islets analysed (n = 15 to 20 islets per animal). Values are mean 6 SEM of 6 observations unless otherwise
indicated. Dp,0.05 compared to respective non-pregnant controls. *p,0.05, **p,0.01, ***p,0.001 compared to non-pregnant or pregnant C57BL/6
mice. ND, none detected.
doi:10.1371/journal.pone.0096863.g001
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(red) (Figure 5A). Further evaluation revealed a substantial
increase of glucagon deficient, GLP-1 positive or GIP positive
cells in islets of pregnant C57BL/6 mice (Figures 4C and 5C). In
contrast to both groups of KO mice, such cell populations were
not observed in islets of non-pregnant C57BL/6 mice (Figures 4C
and 5C). Pregnancy lowered GLP-1/glucagon colocalization in
C57BL/6 mice (p,0.001, Figure 5B). GLP-1/glucagon colocali-
zation in non-pregnant GLP-1RKO mice was significantly lower
than non-pregnant C57BL/6 mice (p,0.001, Figure 5B), which
was due to increased numbers of cells with predominant GLP-1
expression in GLP-1RKO mice (Figure 5C).
Representative islets showing PC2/glucagon, PC1/3/glucagon
immunoreactivity from non-pregnant and pregnant C57BL/6,
GLP-1RKO and GIPRKO mice are shown in Figure 6A. PC2
and glucagon colocalization was not altered by pregnancy in any
of the groups, despite strong tendency for reduction in GIPRKO
mice (Figure 6B). Impairment of GIPR signalling reduced PC2/
glucagon colocalization (p,0.05, Figure 6B). Pearson’s colocaliza-
Figure 2. Islet analysis. A: Representative images showing islets from non-pregnant and pregnant C57BL/6, GLP-1RKO and GIPRKO mice are
shown. B: Number of islets, expressed as count per mm2 of pancreas. Values are mean 6 SEM of 6 observations unless otherwise indicated. *p,0.05,
**p,0.01, ***p,0.001 compared to non-pregnant or pregnant C57BL/6 mice.
doi:10.1371/journal.pone.0096863.g002
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tion coefficient for PC2/glucagon colocalization was approxi-
mately 0.7 while that for PC1/3/glucagon colocalization was
approximately 0.2, clearly indicating that PC2 is the predominant
prohormone convertase in alpha cells. Nevertheless, PC1/3 was
detectable at low levels, as evidenced by positive values for
colocalization coefficient (values closer to 21.0 represent no
colocalization). PC1/3 levels in pregnant C57BL/6 mice were
significantly increased (p,0.05, Figure 6C). PC1/3/glucagon
colocalization in pregnant receptor knockout mice was signifi-
cantly lower than pregnant C57BL/6 mice (p,0.05, Figure 6C).
Pregnancy increases intestinal K/L cell count
Representative images showing GLP-1 or GIP positive cells in
small intestinal mucosa of non-pregnant and pregnant C57BL/6,
GLP-1RKO and GIPRKO mice are shown in Figure 7A.
Pregnancy significantly increased intestinal K and L cell count
in C57BL/6 and GIPRKO mice (p,0.05, p,0.01, Figure 7B, C).
In GLP-1RKO mice, pregnancy increased K cell count but did
not affect L cell count (p,0.01, Figure 7B, C). Defective receptor
signalling decreased K and L cell count in GIPRKO mice and L
cell count in GLP-1RKO mice compared to non-pregnant
C57BL/6 mice (p,0.05, p,0.01, Figure 7B, C). Pregnancy did
not affect villus length but defective receptor signalling significantly
decreased villus length (p,0.01, p,0.001, Figure 7D).
Pregnancy alters pancreatic, intestinal and plasma
content of glucagon, GLP-1, GIP and insulin
Pregnancy did not affect pancreatic glucagon content in any of
the groups but pancreatic glucagon content in pregnant GLP-
1RKO mice was significantly lower than pregnant C57BL/6 mice
(p,0.01, Figure 8A). Pregnancy markedly increased pancreatic
GLP-1, GIP and insulin content in C57BL/6 mice (p,0.05, p,
0.01, Figure 8B, C, D) and pancreatic insulin content in GIPRKO
mice (p,0.05, Figure 8D). Defective GLP-1R signalling in non-
pregnant mice markedly increased pancreatic GLP-1 and GIP
content (p,0.01, p,0.001, Figure 8B, C) which was significantly
reduced by pregnancy (p,0.05, Figure 8B, C). Pregnancy also
decreased pancreatic insulin content in GLP-1RKO mice (p,
0.05, Figure 8D). Defective GIPR signalling increased pancreatic
GIP content (p,0.001, Figure 8C) which was unaffected in
pregnancy. Pancreatic GIP and insulin content was significantly
lower in pregnant GLP-1RKO mice when compared to pregnant
C57BL/6 mice (p,0.05, Figure 8C, D).
Pregnancy markedly increased intestinal GLP-1 and GIP
content in C57BL/6 mice but not in other groups (p,0.05,
Figure 8E, F). Defective GLP-1 and GIP receptor signalling
markedly reduced intestinal GLP-1 content (p,0.05, p,0.001,
Figure 8E). Impairment of GLP-1 receptor signalling increased
intestinal GIP content (p,0.01, Figure 8F), but levels were
significantly decreased in pregnancy, compared with pregnant
control C57BL/6 mice (p,0.05, Figure 8F). Intestinal GIP
content was also reduced in pregnant GIPRKO mice when
compared to pregnant C57BL/6 mice (p,0.01, Figure 8F).
In C57BL/6 mice, pregnancy significantly decreased plasma
glucagon while it significantly increased plasma GIP and insulin,
but not GLP-1 (p,0.05, p,0.01, Figure 8G, H, I, J). Pregnancy
significantly decreased plasma GIP levels in GLP-1RKO mice (p,
0.01, Figure 8I). Defective receptor signalling did not affect
Figure 3. Proliferation and apoptosis frequencies. A: Representative islets showing insulin (red) and Ki67 (green, indicated by arrows), insulin
(red) and TUNEL (green, indicated by arrows) immunoreactivity from non-pregnant and pregnant C57BL/6, GLP-1RKO and GIPRKO mice are shown. B:
Beta cell proliferation frequency, expressed as % of beta cells analysed. C: Beta cell apoptosis frequency, expressed as % of beta cells analysed. D:
Ki67/TUNEL ratio. Values are mean 6 SEM of 6 observations unless otherwise indicated. DDDp,0.001 compared to respective non-pregnant controls.
**p,0.01, ***p,0.001 compared to non-pregnant or pregnant C57BL/6 mice.
doi:10.1371/journal.pone.0096863.g003
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Figure 4. Glucagon and GIP colocalization. A: Representative islets showing glucagon (green) and GIP (red, indicated by block arrows)
immunoreactivity from non-pregnant and pregnant C57BL/6, GLP-1RKO and GIPRKO mice are shown. Dotted arrows indicate alpha cells expressing
mainly of GIP. B: GIP/glucagon colocalization, expressed in terms of Pearson’s coefficient of colocalization. C: Islets with GIP+ glucagon2 cells,
expressed as % of total islets analysed (n = 15 to 20 islets per animal). Values are mean6 SEM of 6 observations unless otherwise indicated. Dp,0.05,
DDp,0.01 compared to respective non-pregnant controls. ND, not detected.
doi:10.1371/journal.pone.0096863.g004
Figure 5. Glucagon and GLP-1 colocalization. A: Representative islets showing glucagon (green) and GLP-1 (red, indicated by block arrows)
immunoreactivity from non-pregnant and pregnant C57BL/6, GLP-1RKO and GIPRKO mice are shown. Dotted arrows indicate alpha cells expressing
mainly of GLP-1. B: GLP-1/glucagon colocalization, expressed in terms of Pearson’s coefficient of colocalization. C: Islets with GLP-1+ glucagon2 cells,
expressed as % of total islets analysed. Values are mean 6 SEM of 6 observations. DDDp,0.001 compared to respective non-pregnant controls. ***p,
0.001 compared to non-pregnant or pregnant C57BL/6 mice. ND, not detected.
doi:10.1371/journal.pone.0096863.g005
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Figure 6. Glucagon and PC2 or PC1/3 colocalization. A: Representative islets showing glucagon (green) and PC2 (red, indicated by block
arrows), glucagon (green) and PC1/3 (red, indicated by block arrows) immunoreactivity from non-pregnant and pregnant C57BL/6, GLP-1RKO and
GIPRKO mice are shown. B: PC2/glucagon colocalization, expressed in terms of Pearson’s coefficient of colocalization. C: PC1/3/glucagon
colocalization, expressed in terms of Pearson’s coefficient of colocalization. Values are mean 6 SEM of 6 observations. Dp,0.05 compared to
respective non-pregnant controls. *p,0.05 compared to non-pregnant C57BL/6 mice.
doi:10.1371/journal.pone.0096863.g006
Figure 7. Intestine analyses. A: Representative images showing GLP-1 or GIP (green) positive cells in intestinal mucosa of non-pregnant and
pregnant C57BL/6, GLP-1RKO and GIPRKO mice are shown. Arrows indicate GLP-1 or GIP positive cells. B: Intestinal K cell count, expressed as count
per mm2 of mucosal area. C: Intestinal L cell count, expressed as count per mm2 of mucosal area. D: Villus length, expressed as mm. Values are mean6
SEM of 6 observations. Dp,0.05, DDp,0.01 compared to respective non-pregnant controls. *p,0.05, **p,0.01, ***p,0.001 compared to non-
pregnant or pregnant C57BL/6 mice.
doi:10.1371/journal.pone.0096863.g007
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circulating levels of glucagon, total GLP-1 or insulin but increased
levels of GIP (p,0.05, p,0.01, Figure 8I). Pregnancy did not alter
plasma glucose in any of the groups although plasma glucose levels
in non-pregnant GLP-1RKO mice were significantly higher than
C57BL/6 mice (p,0.05, Figure 8K).
Discussion
Pregnancy increases metabolic needs and hence alters maternal
metabolism by enhancing nutrient absorption and pancreatic beta
cell function to match increased demand. Earlier reports on
pregnancy-induced beta cell compensation revealed that lacto-
genic hormones stimulate beta cell proliferation and suppress
apoptosis, thereby increasing beta cell mass [36,43–45]. This is
supported by observations in prolactin receptor knockout mice
which displayed an inability to increase beta cell mass during
pregnancy [33,45]. Several reports also claim that lactogenic
hormones increase serotonin biosynthesis in beta cells which in
turn exerts proliferative effects on beta cells [46,47]. In contrast,
the involvement of gut hormones which normally play a key role in
the regulation of beta cell function and survival has been largely
overlooked. Interestingly, Sugiyama et al. observed that beta cell
proliferation was not affected in pregnant glucagon-GFP knock-in
(Gcggfp/Gcggfp) mice lacking global proglucagon derived peptides,
including glucagon, GLP-1, GLP-2 and oxyntomodulin [48].
However, recent studies have shown that these mice display
important compensatory changes even in the non-pregnant state,
including markedly increased circulating GIP with substantial
ectopic expression of GIP in islet beta cells [29]. Thus, a positive
role of GIP on beta cell mass may be particularly important in
these animals. Accordingly, further studies are required using
more specific receptor knockout models without functional GLP-1
or GIP receptors to assess the true role of incretin hormones in islet
cell adaptations to pregnancy.
Our study using GLP-1R and GIPR knockout animal models
revealed that receptor knockout did not affect islet area and beta
cell area but increased alpha cell area without affecting pancreatic
glucagon content in GIPRKO. As noted by Ling et al (2001),
impairment of GLP-1R signalling did not affect pancreatic insulin
or glucagon but increased the number of islets with centralised
alpha cells [49]. Abolition of incretin signalling also decreased the
number of islets in both groups of KO mice, possibly reflecting the
impact of this pathway in postnatal neogenesis as suspected in
transgenic mice overexpressing a dominant negative GIP receptor
[50]. Recent studies have demonstrated the expression and
secretion of GIP and GLP-1 in islets [20–26,28]. Using specific
antibodies, we consistently observed co-localisation of GIP, GLP-
1, PC2 and PC1/3 together with glucagon in the alpha cells of
normal as well as incretin receptor knockout mice. Further,
appreciable amounts of GIP and GLP-1 were measured in
pancreatic extracts, representing 11–15% of that present in the
intestines. Knockout of GLP-1R resulted in compensatory
increases in both pancreatic GIP and GLP-1, whereas abolition
of GIPR increased pancreatic GIP. Interestingly, GLP-1R
Figure 8. Pancreatic, intestinal and plasma levels of hormones. A: Pancreatic glucagon content, expressed as pmol/mg protein. B: Pancreatic
GLP-1 content, expressed as pmol/mg protein. C: Pancreatic GIP content, expressed as pmol/mg protein. D: Pancreatic insulin content, expressed as
nmol/mg protein. E: Intestinal GLP-1 content, expressed as pmol/mg protein. F: Intestinal GIP content, expressed as pmol/mg protein. G: Plasma
glucagon, expressed as pmol/l. H: Plasma total GLP-1, expressed as pmol/l. I: Plasma GIP, expressed as pmol/l. J: Plasma insulin, expressed as pmol/l. K:
Plasma glucose, expressed as mmol/l. Values are mean 6 SEM of 4 observations unless otherwise indicated. Dp,0.05, DDp,0.01 compared to
respective non-pregnant controls. *p,0.05, **p,0.01, ***p,0.001 compared to non-pregnant or pregnant C57BL/6 mice.
doi:10.1371/journal.pone.0096863.g008
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knockout mice exhibited a substantial increase in peripherally
located islet cells which were either GLP-1 or GIP positive but
glucagon deficient. GIPR KO mice similarly displayed substantial
numbers of GLP-1 positive, glucagon deficient islet cells. The
decrease of GLP-1/glucagon colocalization in alpha cells of GLP-
1RKO and GIPRKO mice suggests that these incretin producing
cells are derived from alpha cells. Indeed, there is evidence for a
switch from PC2 to PC1/3 in islets exposed to increased functional
demand or cytotoxic insult [20,22,24,25]. Taken together, these
observations in normal and knockout mice suggest that paracrine
and other intra-islet effects of locally produced GIP and GLP-1 are
likely to exert significant effects given their established actions on
islet cell function [1–4,41].
In contrast to the pancreas, few comprehensive observations
have been made on the intestines of GLP-1R or GIPRKO mice.
We observed that impairment of GLP-1R signalling decreased
villus length, intestinal L cell count and GLP-1 content, with the
expected compensatory increases of intestinal and circulating GIP
[41,51]. On the other hand, GIPRKO mice exhibited decreases in
villus length, intestinal K and L cell counts and intestinal GLP-1
content, with paradoxical increase in circulating GIP. Others have
reported normal or slightly elevated circulating GIP concentra-
tions [52]. Thus, these data indicate that both GLP-1 and GIP are
intimately involved in maintenance and function of incretin-
producing enteroendocrine cell populations. It also appears that
lack of functional GLP-1 is well compensated by enhancement of
GIP, whereas compromised GIP action was not met with increases
in circulating GLP-1.
As expected, pregnancy induced notable changes in the islet
parameters of C57BL/6 mice, with increases in islet area, numbers
of medium and large sized islets, beta cell area and both pancreatic
and circulating insulin [33,46,48]. Pregnancy did not affect alpha
cell area, pancreatic glucagon content or islet number, indicating
that pregnancy was associated with expansion of beta cell mass
rather than significant islet neogenesis as considered by others
[53,54]. GIP and GLP-1 were clearly expressed in islet alpha cells
of pregnant mice and there was a substantial increase in
peripherally located cell populations expressing only GIP or
GLP-1. Consistent with these changes pancreatic levels of both
GIP and GLP-1 were increased together with up-regulation of
alpha cell PC1/3, as observed previously [22]. These changes
were not accompanied by increases in GLP-1/glucagon coloca-
lization but this could reflect a suspected increase of alpha cells
expressing only GLP-1, hence giving a lower value for the
colocalization coefficient. Similarly pregnancy increased intestinal
contents of both incretin hormones and the numbers of intestinal
K- and L-cells, resulting in increased circulating levels of GIP but
notably no change in GLP-1. Consistent with negative intra-islet
regulation by increased beta cell numbers and insulin content [55–
57], plasma glucagon levels were decreased by pregnancy.
The changes considered above indicate significant adaptation of
islets in pregnancy and suggest that they may be partly due to
intra-islet production of GLP-1 and GIP which exerts local effects
on beta cell function, including stimulation of beta cell prolifer-
ation and inhibition of apoptosis. The observed increase of
circulating GIP suggests possible involvement of K-cell derived
GIP but contrary to such a view, the pregnancy-induced changes
in the islets of GIPR KO mice were similar to pregnant C57BL/6
mice. This included prominent increases in islet area, beta cell
area and pancreatic insulin content together with decreased islet
GIP/glucagon colocalization and no increase in the population of
cells solely expressing GLP-1. Thus it appears that intestinal or
islet derived GIP plays little role in islet adaptation to pregnancy.
However, in marked contrast, pregnant GLP-1R KO mice
exhibited no adaptive changes in any of these islet parameters
and displayed an actual decrease of islet numbers. Consistent with
decreased beta cell mass, the ratio of Ki67/TUNEL positive
insulin positive cells in pregnant GLP-1R KO mice did not favour
proliferation. Since circulating GLP-1 was unchanged in these
animals, loss of islet compensation is more likely to be due to
abolition of the intra-islet effects of islet-derived GLP-1. Further-
more in GLP-1RKO mice, pregnancy was not associated with
increases in populations of islet cells purely expressing GLP-1 or
GIP and there was a decrease in numbers of alpha cells co-
expressing GIP and glucagon. Pancreatic GLP-1, GIP and insulin
were actually decreased and the pregnancy-induced increases in
intestinal GLP-1 and GIP together with L-cell hyperplasia were
abolished. Taken together, these data reveal an essential role of
GLP-1 in islet compensation to pregnancy, suggesting crucial
involvement of changes in proglucagon processing in islet cells
leading to local generation of GLP-1. Clearly generation of
transgenic mice with targeted knockout of beta cell GLP-1
receptor could be useful to separate out any indirect effects.
The mechanisms responsible for effects of GLP-1 on beta cell
mass clearly involve stimulation of beta cell proliferation and
inhibition of apoptosis. Evidence suggests that this is regulated by
PI3K signalling pathway [58–62]. Clearly other factors such as
estrogens, prolactin, serotonin and placental hormones may feed
into the signalling pathways including involvement of PI3K for
estrogens and prolactin. Further, although evidence is lacking, we
cannot rule out possible effects of GLP-1RKO on secretion of
pituitary hormones such as prolactin. Future research to under-
stand the expansion of beta cell mass in human islets and the
underlying involvement of GLP-1 activated pathways may well
open up new avenues to enhance beta cell mass for the treatment
of diabetes.
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